Of the molecular biochemical alterations that occur during apoptosis, activation of caspases, notably caspase-3, is probably the most attractive for developing specific in vivo molecular imaging probes. We recently designed a library of isatin-5 sulfonamides and selected [ 18 F]ICMT-11 for further evaluation on the basis of subnanomolar affinity for activated capsase-3, high metabolic stability, and facile radiolabeling. In this present study, we have demonstrated that [ 18 F]ICMT-11 binds to a range of drug-induced apoptotic cancer cells in vitro and to 38C13 murine lymphoma xenografts in vivo by up to 2-fold at 24 h posttreatment compared to vehicle treatment. We further demonstrated that the increased signal intensity in tumors after drug treatment, detected by whole body in vivo microPET imaging, was associated with increased apoptosis. In summary, we have characterized [ 18 F]ICMT-11 as a caspase-3/7 specific PET imaging radiotracer for the assessment of tumor apoptosis that could find utility in anticancer drug development and the monitoring of early responses to therapy.
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cell death ͉ response to treatment ͉ small animal imaging A poptosis is an essential process for eliminating unwanted cells during embryonic development, growth, differentiation, and maintenance of tissue homeostasis. Deregulation of apoptosis signaling pathways is, therefore associated with various pathologies including autoimmunity, neurodegeneration, cardiac ischemia, and transplant rejection (1) , and the capacity to evade apoptosis has been defined as one of the hallmarks of cancer (2) . Moreover, because effective anticancer therapy often requires induction of tumor cell death through apoptosis, monitoring of this process could provide important predictive outcome information in the context of routine patient management and early clinical trials (3, 4) . A noninvasive apoptosis imaging technology will permit the detection of tumor biological changes that evolve within hours of initiating treatment compared to changes in tumor size, the basis for Response Evaluation Criteria in Solid Tumors (RECIST) guidelines (5) that evolves within months.
In cancer, apoptosis is induced by a large variety of stimuli including cytotoxic and mechanism-based therapeutics, and radiotherapy. Although those stimuli trigger different apoptotic signaling pathways, the molecular events in the execution phase of apoptosis are largely shared and involve the caspases, which constitute a family of cysteine proteases that cleave their substrate after specific tetrapeptide motifs. Within the caspase family, the effector caspases (caspases-3, -6, and -7) orchestrate the demolition phase of apoptosis that results in the controlled dismantling of a range of key structures within the cell and its subsequent disposal (6) . Moreover, one of the most noticeable and specific features of apoptosis is the degradation of the DNA into numerous fragments, often down to multiples of 200 base pairs, driven by the activation of caspase-3 (7), the central effector caspase, which makes it an attractive biomarker of apoptosis.
Given its central role, various nonpeptide small molecule inhibitors of the isatin sulfonamide class that bind selectively to the active site of caspase-3 (and -7), have been described, initially as potential inhibitors of apoptosis (8, 9) . Furthermore, recent reports described the utility of [ 18 F]-radiolabeled isatins as probes for PET imaging of apoptosis (10) (11) (12) (13) (14) , one of them using an experimental rat model of drug-induced liver apoptosis (15) . To date, no study has however reported imaging of tumor models by this strategy. Given that patient tumors typically show low levels of apoptosis at baseline and a relatively small increase after drug treatment (2-to 6-fold increase corresponding to 5-15% apoptosis) (16, 17) , it is important to demonstrate the potential of new imaging agents in relevant tumor models. In the attempt to design a PET imaging tracer for the detection of anticancer drug-induced tumor apoptosis, we previously screened a focused library of isatin-based caspase-3/7 inhibitors and identified a isatin 5-sulfonamide, ICMT-11 (isatin-15 in Ref. 18) , with subnanomolar affinity for caspase-3 and moderate lipophilicity (18) . In the same report, we synthesized the radiolabeled [ 18 F]ICMT-11 ( Fig. 1A) by a 'click radiochemistry' approach and demonstrated its high metabolic stability, suggesting that [ 18 F]ICMT-11 would make a suitable caspase-3/7 specific PET imaging tracer.
The current study aims to investigate and validate the ability of [ 18 F]ICMT-11 to noninvasively image the drug-induced tumor apoptotic process in vivo, as well as, its potential for the early detection and monitoring of response to anticancer therapy.
Results
In Vitro [ 18 F]ICMT-11 Binding and Caspase-3/7 Activation in DrugTreated Cancer Cells. We first investigated the binding potential of [ 18 F]ICMT-11 in cells undergoing anticancer drug-induced cell death in vitro and showed that the murine fibrosarcoma RIF-1 and human pulmonary carcinoma LNM35 cells treated with the topoisomerase inhibitor etoposide or the alkylating agent cisplatin showed higher [ 18 F]ICMT-11 binding in drug-treated cells compared to control by up to 2-fold (left panels Fig. 1 B and C,  respectively) . We demonstrated the relevance of this binding by confirming that increased [ 18 F]ICMT-11 binding in drug-treated cells corresponded to higher cellular caspase-3/7 activity (right panels Fig. 1 B and C) . Of note, the control baseline uptake for [ 18 F]ICMT-11 was higher than that for the caspase-glo assay and that may be inherent in the two detection methods, direct binding to activated caspase-3 and hence, cellular retention versus caspase-3 enzymatic activity, respectively. Moreover, there was no increased [ 18 F]ICMT-11 binding in caspase-3-deficient MCF-7 human breast cancer cells (19) treated with the alkylating agent 4-hydroperoxycyclophosphamide (4-HC) compared to control (Fig. S1) cells used for the binding assay to an Annexin V/PI flow cytometry analysis, as it is commonly used for in vitro cell death assessment. This assay is based on the Annexin V detection of actively externalized phosphatidylserine on the plasma membrane outer surface of apoptotic cells and the PI staining of necrotic cells with compromised plasma membrane. Three cell populations were defined on the flow cytometry chart: viable cells (R1), apoptotic cells (R2), and necrotic cells (R3) (Fig. 2C ). According to this definition, the 2-fold increase [ 18 F]ICMT-11 binding in 4-HC-treated cells was associated with 17.93% apoptotic cells. However, the R3 region cannot discriminate between the late apoptotic cell population, containing activated caspase-3, and necrotic cells as both of them are characterized by a double Annexin V/PI positive staining (membrane phosphatidylserines external exposure and loss of their membrane integrity) (23) . As the R3 region should mirror the Q2ϩQ4 (necrosis and late apoptosis, respectively) quadrants in Fig. 2B (Fig. 2D ). This finding suggests that [ 18 F]ICMT-11 cell uptake is not related to increased cell permeability in apoptotic cells. In contrast, the apparent lower [ 18 F]ICMT-18 uptake in 4-HC-treated cells compared to control is probably due to a more active washout of the unbound tracer in membrane compromised apoptotic cells. We further examined the specificity of [ 18 F]ICMT-11 in a model of necrosis. The data were inconclusive and a more appropriate in vivo experimental model of tumor necrosis is desirable to elucidate specificity of binding to apoptotic versus necrotic cells (Fig. S2) . [ 18 F]ICMT-11 PET imaging was performed 24 h after the treatment of 38C13 xenograft-bearing mice with 100 mg/kg cyclophosphamide (CPA) or vehicle, and tumor was subsequently excised for tracer biodistribution assessment and histology. In our experimental model of apoptosis, no overall toxicity with respect to body weight loss was observed at the dose of cyclophosphamide used; the drug is tolerated at a dose 170 mg/kg cyclophosphamide every 6 days in mice (25) . PET images showed low uptake of the radiotracer in tumors from vehicletreated mice (Fig. 3A) . Overall, high background uptake was seen in liver, small intestine and urine (data not shown). This was consistent with our previously reported normal tissue biodistribution of [ 18 F]ICMT-11 that indicated rapid distribution of the radiotracer to tissues together with rapid elimination mostly via hepatic and renal routes, as suggested by the high localization of [ 18 F]ICMT-11 in the liver, small intestine, kidney and urine (18) . The high uptake in small intestine could also be due in part to high physiological apoptosis of enterocytes at the villus tips and of macrophages within the intestinal lamina propria (26) ; this aspect requires further investigation. In contrast to the low tumor radiotracer uptake in vehicle-treated mice, PET images of CPA-treated mice showed a clear increased tumor uptake of [ 18 F]ICMT-11 (Fig. 3A) . This was confirmed by gamma counting of tumor radioactivity after imaging; there was a significant 1.5-fold increased tumor uptake of [ 18 F]ICMT-11 in CPAtreated mice compared to vehicle (Fig. 3B) . The tumor time versus radioactivity curves (TACs) determined from region of interest analysis of the imaging data (Fig. 3C) were shifted up following treatment with CPA suggesting radiotracer retention. Furthermore, PET imaging variables (NUV 60 , AUC and FRT) extracted from TACs were higher with CPA compared to vehicle treatment (2.1-, 1.6-, and 1.6-fold higher, respectively, Fig. 3D) . Notably, voxel-wise analysis of the PET data, depicting heterogeneity, showed an increase in the number of voxels with high intensity in tumor ROIs of CPA injected mice compared to vehicle (a 1.5-fold group average induction in the 75%-90% percentiles and maximum intensity values, Fig. 4 A and B) . We further established a parallel between tumor [ 18 F]ICMT-11 uptake and apoptosis. Histological analysis of formalin fixed tumor tissues showed that CPA treatment significantly increased apoptosis defined by increased apoptotic bodies (visualized with H&E staining), increased active caspase-3 and fragmented DNA staining (6.5-and 9.8-fold induction, respectively, 8.2-fold induction for combination), together with a significant decrease of DNA content (Fig. 5 ). Of note, there was also a marked reduction in tumor sizes at 24 h in the CPA-treated mice (approximatively 83% that of vehicle-treated mice tumors; not shown). These results establish [ 18 F]ICMT-11 as a good pharmacodynamic marker of apoptosis.
Discussion
We have demonstrated from in vitro binding and PET imaging analysis that [ 18 F]ICMT-11 has utility for detection and quan- tification of tumor apoptosis as early as 24 h after treatment, and describe for the first time a caspase-3/7 specific PET tracer for tumor apoptosis imaging. A number of noninvasive apoptosis imaging approaches have been developed based on the recognition of selective apoptotic biochemical and morphological features coupled to dedicated imaging modalities. These include magnetic resonance spectroscopy (MRS) measurements of cytoplasmic lipid droplet accumulation (27) , magnetic resonance imaging (22) measurements of the apparent diffusion coefficient of water (28) and the C2A domain of synaptotagmin (29) , high frequency ultrasound detection of cell morphology (30) , and the well known annexin V and membrane active nuclear imaging methods (31) (32) (33) . Of these, the annexin V method, based on the detection of phosphatidylserine asymmetric distribution perturbation in apoptotic cells, is arguably the most widely used, preclinically and in humans. This approach has some major drawbacks limiting its routine clinical application including poor biodistribution and clearance of the radiotracer, and nonspecificity to apoptosis. More recently attention has turned to the isatin sulfonamide class of compounds as potential PET radiotracers (8, 10, 12, 13, 15, 18 (34) (35) (36) . Notably, however, baseline uptake in tumors was low, representing nonspecific reversible distribution. This means that use of anatomical imaging, such as computed tomography for localization of the tumor may be mandatory in the translation of this technology into clinical practice. Furthermore, the PET images showed a high retention of the tracer in the liver and intestines, which might limit interpretation of [ 18 F]ICMT-11 PET images of the abdominal region. The high tissue uptake is unlikely to be due to nonspecific recognition of other caspases as [ 18 F]ICMT-11 shows Ϸ10,000-fold selectivity for caspase-3 over other caspases (except caspase-7), activated or otherwise. It is likely that this high background localization is due to metabolic turnover in liver and elimination via the gut (18) . This study suggests that [ 18 F]ICMT-11 PET imaging will be useful for the monitoring of response to therapy rather than diagnosis and localization of tumors per se assessed through conventional clinical imaging. The dynamic range of the imaging approach was found to be lower than that of histology. The 8.2-fold increase in histological tumor apoptosis relative to the up to 2-fold increase in [
18 F]ICMT-11 NUV 60 is likely due to differences in the experimental assessment of apoptosis by the two methods (immunohistochemistry versus radiotracer pharmacokinetics and selective binding). Moreover, because of tumor heterogeneity, the strength of [
18 F]ICMT-11 imaging interpretations could benefit from a systematic voxel-wise data analysis allowing the selection of specific regions of interest within the tumor tissue. By analogy to flow cytometry analysis of cells, we speculate that these parameters will be more sensitive when subjects are used as their own controls as in clinical PET imaging protocols. Our current protocol did not permit this strategy to be assessed since we planned to compare the histology of individual mice to radiotracer uptake. Future studies will explore this possibility.
In summary, we have demonstrated that [ 18 F]ICMT-11 is a sensitive and selective pharmacodynamic marker of caspase-3/7 activation and apoptosis in vivo with potential utility in nonabdominal malignancies. [
18 F]ICMT-11 detects caspase-3/7 cleavage-an early event in apoptosis-and the paradigm has the capacity to be improved in the future for measuring more precisely the amount of cell death in a reproducible manner.
Materials and Methods
Radiopharmaceuticals and Drugs. The radiosynthesis of the caspase-3/7 high affinity inhibitor [ 18 F]ICMT-11 has been described previously (18) . Briefly, (37) . Therefore, 4-hydroperoxycyclophosphamide (4-HC), which spontaneously converts to 4-hydroxycyclophosphamide in aqueous solution (the primary active metabolite of cyclophosphamide) was purchased from Niomech (IIT GmbH) and used in the cell-based assays.
In Vitro [ 18 F]ICMT-11 Binding and Caspase-3/7 Activation Assays. Cells were plated in triplicate in 12-well plates 2 or 3 days before the experiments and treated with indicated drug or corresponding vehicle (DMSO and water for cisplatin/etoposide and 4-HC respectively) for 24 h to induce apoptosis, or submitted to a 56°C heat shock for 30 min to induce necrosis. On the day of the experiment, Ϸ0.37 MBq/well of [ 18 F]ICMT-11 (or [ 18 F]ICMT-18) was added and allowed to accumulate into cells for 60 min at 37°C. Cells were collected, washed, and resuspended in PBS. For the chase time experiment, the cells are washed once and subjected to additional 60 min incubation in normal growth medium. Samples were transferred into counting tubes and fluorine-18 radioactivity was immediately determined using a Packard Cobra II gamma counter (Perkin-Elmer). Luminescent caspase-3/7 activation assay was performed on each sample according to the manufacturer's instructions (CaspaseGlo 3/7 assay, Promega). Briefly, cells were transferred in a white opaque 96-well plate, incubated for 1 h with Caspase-Glo reagent and the enzymatic activity of caspase-3/7 was measured using a Multiskan Luminometer (Thermo Electron). To enable normalization of data to total cellular protein content, the Bicinchoninic acid (BCA) protein assay (Pierce) was performed for all samples according to the manufacturer's instructions.
In Vitro Apoptosis Flow Cytometry Assay. Aliquots of a 38C13 cell suspension used for the binding assay were withdrawn before addition of [ 18 F]ICMT-11 and the cells were doubly stained with either fluorescent inhibitor of caspases-3/7 (FLICA) and propidium iodide (PI) or Annexin V-FITC and PI, according to the instructions of the manufacturer (Vybrant FAM Caspase-3 and -7 and Vybrant Apoptosis assays respectively, Invitrogen). A flow cytometry analysis was then performed using the CyAn™ ADP cytometer and Summit v4.3 software (Dako). Data were analyzed by setting quadrants Q and regions R based on the single staining controls. When xenografts reached Ϸ100 mm 3 , the mice were injected with cyclophosphamide (100 mg/kg i.p., n ϭ 3) or vehicle (water, n ϭ 3). At 24 h posttreatment, the animals were scanned on a dedicated small animal PET scanner (Siemens Inveon PET module, Siemens Molecular Imaging Inc.) following a bolus i.v. injection of Ϸ3.7 MBq of [ 18 F]ICMT-11. Dynamic emission scans were acquired in list mode format over 60 min. The acquired data were then sorted into 0.5-mm sinogram bins and 19 time frames for image reconstruction, which was done by filtered back projection. Cumulative images of the dynamic data (0 to 30 min) were iteratively reconstructed (OSEM3D) and used for visualization of radiotracer uptake and to define the regions of interest (ROIs) with the Siemens Inveon Research Workplace software (three-dimensional ROIs were defined for each tumor). The count densities were averaged for all ROIs at each of the 19 time points to obtain a time versus radioactivity curve (TAC). Tumor TACs were normalized to that of whole body at each of the time points to obtain the normalized uptake value (NUV). Direct [ 18 F]ICMT-11 tumor uptake was assessed subsequent to the PET scan. For this, blood was taken by cardiac puncture from the animals and tumors were excised. The tissues were weighted and immediately counted for fluorine-18 radioactivity. Data were expressed as tumor to blood ratio.
Active Caspase-3 and TUNEL Immunohistochemistry Assay. Following PET imaging studies, tumor tissues were excised, fixed in formalin, embedded in paraffin, sectioned (5 m slices) and processed for active caspase-3 and DNA degradation terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) fluorescent detection assays using the Cleaved Caspase-3 (Asp 175) monoclonal antibody (Cell Signaling Technology) coupled with the Alexa Fluor 594 goat anti-rabbit (Invitrogen) and the In Situ Cell Death Detection Kit (Roche), respectively. The ProLong Gold Antifade mounting solution (Invitrogen) containing 4Ј,6-diamidino-2-phenylindole (DAPI) was added to tissue sections prior coverslips mounting. All assays were performed according to the manufacturer instructions and sections were counterstained with hematoxylin and eosin (H&E) staining. Images from two histological sections separated by 1 mm, 10 random fields per section (at 400ϫ magnification), were captured using an Olympus BX51 fluorescent microscope and the staining intensities were determined using the ImageJ software [National Institutes of Health (NIH)].
Statistical Analysis. Data were expressed as mean Ϯ standard error of the mean (SEM) and the significance of comparison between two data sets was determined using Student's t test (Prism v5.0 software, GraphPad) and defined as significant ( * , 0.01 Ͻ P Ͻ 0.05), very significant ( ** , 0.001 Ͻ P Ͻ 0.01), and extremely significant ( *** , P Ͻ 0.001).
